Corvidia Therapeutics is a clinical-stage company focused on the research, development, and commercialization of transformative therapies for cardio-renal diseases, with a pipeline focused on treating Chronic Kidney Disease with atherosclerotic cardiovascular disease and inflammation, and high triglyceride induced Acute Pancreatitis.

Corvidia Therapeutics

At Corvidia Therapeutics, we are creating precision therapies by using the science of genomics in new ways. Through random genetic mutation, nature conducts experiments, subtly changing how key proteins work in our bodies and influencing the factors that drive diseases differently in different groups of patients. We study the networks of these genetic variations and how they affect specific diseases in specific patients, allowing us to understand how a personalized drug in complex diseases may behave before we ever begin a clinical trial.  We believe that by leveraging the inner networks of genomics we can develop therapies tailored to patients across a range of complex diseases. Working together, our team of distinguished scientists, experienced drug developers and a successful group of investors are focused on bringing these innovations to patients. 

COM:CORVIDIATX

Corvidia Therapeutics

locale

market

industry

website

crunchbase

linkedin

founding date

peer of

Metrics